Overview

A Study to Evaluate SIMPONI (Golimumab) Therapy in Children, Adolescents and Young Adults With Pre-Symptomatic Type 1 Diabetes

Status:
Completed

Trial end date:
2021-06-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to determine the safety and tolerability of golimumab in children, adolescents, and young adults with pre-symptomatic stage 2 type 1 diabetes mellitus (T1D).

Phase:

Phase 1

Details

Lead Sponsor:

Janssen Research & Development, LLC

Treatments:

Antibodies, Monoclonal
Golimumab